Research Paper Volume 15, Issue 16 pp 7933—7955
A novel hepatocellular carcinoma-specific mTORC1-related signature for anticipating prognosis and immunotherapy
Figure 6. Investigation of the variation in immunotherapy across mTORC1-related subgroups. (A, B) The boxplots illustrate the immune checkpoints that were upregulated in C1 in comparison with C2 in TCGA-LIHC and ICGC-LIRI-JP cohorts. (C) Variations in the TIDE score and immune response status of the diverse molecular subtypes in the TCGA-LIHC cohort. (D) Variations in the TIDE score and immune response status of the diverse molecular subtypes in the ICGC-LIRI-JP cohort.